Drug Type Small molecule drug |
Synonyms 1-Pyrrolidinecarboximidamide, N-[imino[[4-(trifluoromethoxy)phenyl]amino]methyl]-, acetate (1:1) + [5] |
Mechanism Mitochondrial complex I (NADH dehydrogenase) inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization ImmunoMet Therapeutics, Inc.Startup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC13H16F3N5O |
InChIKeyNGFUHJWVBKTNOE-UHFFFAOYSA-N |
CAS Registry1422365-93-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Lixumistat | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Phase 2 | - | ImmunoMet Therapeutics, Inc.Startup | 31 May 2023 |
Advanced Malignant Solid Neoplasm | Phase 2 | KR | ImmunoMet Therapeutics, Inc.Startup | 09 Oct 2017 |
Lymphoma | Phase 2 | KR | ImmunoMet Therapeutics, Inc.Startup | 09 Oct 2017 |
Advanced Pancreatic Adenocarcinoma | Phase 1 | US | 21 Oct 2022 | |
Pancreatic Cancer | Phase 1 | US | ImmunoMet Therapeutics, Inc.Startup | 21 Oct 2022 |
Castration-Resistant Prostatic Cancer | Preclinical | US | ImmunoMet Therapeutics, Inc.Startup | 31 May 2023 |
Gastrointestinal Stromal Tumors | Preclinical | US | ImmunoMet Therapeutics, Inc.Startup | 31 May 2023 |
Glioblastoma Multiforme | Preclinical | US | ImmunoMet Therapeutics, Inc.Startup | 31 May 2023 |
NCT03272256 (ASCO2020) Manual | Phase 1 | 22 | (oghxrnmepw) = pjtxpkmfug wozopwzdmd (ymbgfypbho ) View more | Positive | 29 May 2020 |